– моментальные уведомления о рынке акций
– моментальные уведомления о рынке акций
DENVER--(BUSINESS WIRE)--Modivcare Inc., (the “Company” or “Modivcare”) (Nasdaq: MODV), a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions focused on improving patient outcomes, today reported financial results for the three months ended March 31, 2022.
First Quarter 2022 Highlights:
“This quarter, we advanced our strategy to improve outcomes and better serve the health needs of patients through our supportive care platform,” said Daniel E. Greenleaf, Modivcare’s President and Chief Executive Officer. “I am very pleased with the recent management appointments at Modivcare which will help us execute on key operational and growth objectives. With disciplined execution from our team and increased momentum from this quarter’s performance, Modivcare is committed to addressing the social determinants of health and removing barriers to accessing care for the 32 million members we serve. I am extremely proud of the incredible work and dedication of our entire organization to accelerate our vision of empowering patients to access care through our integrated platform more easily, efficiently, and effectively.”
First Quarter 2022 Results
For the first quarter of 2022, the Company reported revenue of $574.5 million, an increase of 26.6% from $453.6 million in the first quarter of 2021.
Operating income was $14.9 million, or 2.6% of revenue, in the first quarter of 2022, compared to operating income of $28.8 million, or 6.3% of revenue, in the first quarter of 2021. Net income in the first quarter of 2022 was $0.3 million, or $0.02 per diluted common share, compared to net income of $18.8 million, or $1.31 per diluted common share, in the first quarter of 2021.
Adjusted EBITDA was $50.3 million, or 8.8% of revenue, in the first quarter of 2022, compared to $50.0 million, or 11.0% of revenue, in the first quarter of 2021.
Adjusted Net Income in the first quarter of 2022 was $22.2 million, or $1.57 per diluted common share, compared to $29.6 million, or $2.06 per diluted common share, in the first quarter of 2021.
Comparable adjusted EBITDA and Adjusted Net Income for Q1 2021 was recast to show the impact of cash settled equity, which the Company is now excluding for the purpose of these calculations.
The year-over-year increase in revenue was primarily due to incremental revenue of $44.4 million and $13.9 million associated with the acquisitions of Care Finders and VRI, respectively. NEMT revenue also increased year-over-year due to higher trip volume which drove higher revenue per member in Q1 2022.
Adjusted EBITDA increased in the first quarter of 2022 due to incremental contribution from Care Finders and VRI. This was partially offset by higher corporate general and administrative cost as the Company continued to make investments in its employees and technology.
Modivcare recorded income, net of tax, of $0.5 million related to its Matrix equity investment in Q1 2022 compared to $3.2 million for the first quarter of 2021.
Organizational Consolidation and Change in Segments
Effective January 1, 2022, the Company completed its segment reorganization which resulted in the addition of a Corporate segment that includes the costs associated with the Company's corporate operations. The operating results of our Corporate segment include our activities related to executive, accounting, finance, internal audit, tax, legal and certain strategic and corporate development functions for each segment, as well as the Company's captive insurance program and the results of our Matrix investment. The Company reclassified certain costs associated with this reorganization for the three months ended March 31, 2021 to conform to this presentation.
Investor Presentation and Conference Call
Modivcare will hold a conference call to discuss its financial results on Thursday, May 5, 2022 at 8:00 a.m. ET. To access the call, please dial:
US toll-free: 1 (877) 423 9820 International: 1 (201) 493 6749
You may also access the conference call via webcast at investors.modivcare.com, where the call also will be archived.
About Modivcare
Modivcare Inc. (“Modivcare”) (Nasdaq: MODV) is a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions for public and private payors and their patients. Our value-based solutions address the social determinants of health (SDoH), enable greater access to care, reduce costs, and improve outcomes. We are a leading provider of non-emergency medical transportation (NEMT), personal care and remote patient monitoring. To learn more about Modivcare, please visit www.modivcare.com.
Non-GAAP Financial Measures and Adjustments
In addition to the financial measures prepared in accordance with generally accepted accounting principles in the United States ("GAAP"), this press release includes EBITDA, Adjusted EBITDA and Adjusted EBITDA margin for the Company and its segments, Adjusted Net Income and Adjusted EPS for the Company, and Adjusted G&A expense for the Company’s segments, which are performance measures that are not recognized under GAAP. EBITDA is defined as income (loss) from continuing operations, net of taxes, before: (1) interest expense, net, (2) provision (benefit) for income taxes and (3) depreciation and amortization. Adjusted EBITDA is calculated as EBITDA before (as applicable): (1) restructuring and related charges, including severance and office closure and professional services costs, (2) certain transaction and related costs, (3) cash settled equity, (4) stock-based compensation, (5) COVID-19 related costs, net of grant income, and (6) equity in net (income) loss of investee. Adjusted EBITDA margin is calculated as Adjusted EBITDA, divided by Service revenue, net. Adjusted Net Income is calculated as income from continuing operations, net of taxes, before: (1) restructuring and related charges including severance and office closure and professional services costs, (2) certain transaction and related costs, (3) cash settled equity, (4) stock-based compensation, (5) equity in net (income) loss of investee, (6) intangible amortization expense, (7) COVID-19 related costs, net of grant income, (8) tax impacts from the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act"), and (9) the income tax impact of such adjustments. Adjusted EPS is calculated as Adjusted Net Income less (as applicable): the sum of (1) dividends on convertible preferred stock plus (2) income allocated to participating securities, divided by the diluted weighted-average number of common shares outstanding as calculated for Adjusted Net Income. Adjusted G&A expense is calculated as G&A expense before (as applicable): (1) restructuring and related charges, (2) transaction costs, (3) cash settled equity, and (4) stock-based compensation. Our non-GAAP performance measures exclude expenses and amounts that are not driven by our core operating results and may be one time in nature. Excluding these expenses makes comparisons with prior periods as well as to other companies in our industry more meaningful. We believe such measures allow investors to gain a better understanding of the factors and trends affecting the ongoing operations of our business. We consider our core operations to be the ongoing activities to provide services from which we earn revenue, including direct operating costs and indirect costs to support these activities. In addition, our net income or loss in equity investee is excluded from these measures, as we do not have the ability to manage the venture, allocate resources within the venture, or directly control its operations or performance.
Our non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in our industry, as other companies in our industry may calculate non-GAAP financial measures differently. In addition, there are limitations in using non-GAAP financial measures because they are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies, and exclude expenses that may have a material impact on our reported financial results. The presentation of non-GAAP financial measures is not intended to be considered in isolation from or as a substitute for the most directly comparable financial measures prepared in accordance with GAAP. We urge you to review the reconciliations of our non-GAAP financial measures to the most directly comparable GAAP financial measures included below, and not to rely on any single financial measure to evaluate our business.
Forward-Looking Statements
Certain statements contained in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are predictive in nature and are frequently identified by the use of terms such as “may,” “will,” “should,” “expect,” “believe,” “estimate,” “intend,” and similar words indicating possible future expectations, events or actions. Such forward-looking statements are based on current expectations, assumptions, estimates and projections about our business and our industry, and are not guarantees of our future performance. These statements are subject to a number of known and unknown risks, uncertainties and other factors, many of which are beyond our ability to control or predict, which may cause actual events to be materially different from those expressed or implied herein, including but not limited to: government or private insurance program funding reductions or limitations; alternative payment models or the transition of Medicaid and Medicare beneficiaries to Managed Care Organizations, or MCOs; our inability to control reimbursement rates received for our services; cost containment initiatives undertaken by private third-party payors; the effects of a public health emergency; inadequacies in, or security breaches of, our information technology systems, including the systems intended to protect our clients’ privacy and confidential information; any changes in the funding, financial viability or our relationships with our payors; pandemic infectious diseases, including the COVID-19 pandemic; disruptions to our contact center operations caused by health epidemics or pandemics like COVID-19; delays in collection, or non-collection, of our accounts receivable, particularly during any business integration; an impairment of our long-lived assets; any failure to maintain or to develop further reliable, efficient and secure information technology systems; an inability to attract and retain qualified employees; any acquisition or acquisition integration efforts; our contracts not surviving until the end of their stated terms, or not being renewed or extended; our failure to compete effectively in the marketplace; our not being awarded contracts through the government’s requests for proposals process, or our awarded contracts not being profitable; any failure to satisfy our contractual obligations or to maintain existing pledged performance and payment bonds; a failure to estimate accurately the cost of performing our contracts; any misclassification of the drivers we engage as independent contractors rather than as employees; significant interruptions in our communication and data services; not successfully executing on our strategies in the face of our competition; any inability to maintain relationships with existing patient referral sources; any failure to obtain the consent of the New York Department of Health to manage the day to day operations of our licensed in-home personal care services agency business that we acquired with our personal care segment; acquired unknown liabilities in connection with the acquisition of our personal care segment; changes in the case-mix of our personal care patients, or changes in payor mix or payment methodologies; our loss of existing favorable managed care contracts; our experiencing shortages in qualified employees and management; labor disputes or disruptions, in particular in New York; becoming subject to malpractice or other similar claims; and our reliance on others for the financial condition of our equity investment in Matrix.
The Company has provided additional information about the risks facing our business in our annual report on Form 10-K and subsequent filings most recently filed with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made and are expressly qualified in their entirety by the cautionary statements set forth herein and in our filings with the Securities and Exchange Commission, which you should read in their entirety before making an investment decision with respect to our securities. We undertake no obligation to update or revise any forward-looking statements contained in this release, whether as a result of new information, future events or otherwise, except as required by applicable law.
--financial tables to follow--
Modivcare Inc. |
||||||||
Unaudited Condensed Consolidated Statements of Operations |
||||||||
(in thousands, except share and per share data) |
||||||||
|
|
|
|
|
||||
|
|
Three months ended March 31, |
||||||
|
|
|
2022 |
|
|
|
2021 |
|
|
|
|
|
|
||||
Service revenue, net |
|
$ |
574,475 |
|
|
$ |
453,610 |
|
Grant income |
|
|
468 |
|
|
|
2,648 |
|
|
|
|
|
|
||||
Operating expenses: |
|
|
|
|
||||
Service expense |
|
|
459,315 |
|
|
|
360,333 |
|
General and administrative expense |
|
|
76,808 |
|
|
|
54,925 |
|
Depreciation and amortization |
|
|
23,946 |
|
|
|
12,239 |
|
Total operating expenses |
|
|
560,069 |
|
|
|
427,497 |
|
|
|
|
|
|
||||
Operating income |
|
|
14,874 |
|
|
|
28,761 |
|
|
|
|
|
|
||||
Other expenses: |
|
|
|
|
||||
Interest expense, net |
|
|
15,400 |
|
|
|
8,423 |
|
Income (loss) before income taxes and equity method investment |
|
|
(526 |
) |
|
|
20,338 |
|
Provision (benefit) for income taxes |
|
|
(361 |
) |
|
|
4,739 |
|
Equity in net income of investee, net of tax |
|
|
(483 |
) |
|
|
(3,241 |
) |
Net income |
|
$ |
318 |
|
|
$ |
18,840 |
|
|
|
|
|
|
||||
Earnings per common share: |
|
|
|
|
||||
Basic |
|
$ |
0.02 |
|
|
$ |
1.33 |
|
Diluted |
|
$ |
0.02 |
|
|
$ |
1.31 |
|
|
|
|
|
|
||||
Weighted-average number of common shares outstanding: |
|
|
|
|
||||
Basic |
|
|
14,023,585 |
|
|
|
14,158,666 |
|
Diluted |
|
|
14,143,548 |
|
|
|
14,362,226 |
|
Modivcare Inc. |
||||||
Unaudited Condensed Consolidated Balance Sheets |
||||||
(in thousands) |
||||||
|
|
|
|
|
||
|
|
March 31, 2022 |
|
December 31, 2021 |
||
Assets |
|
|
|
|
||
Current assets: |
|
|
|
|
||
Cash and cash equivalents |
|
$ |
194,063 |
|
$ |
133,139 |
Accounts receivable, net |
|
|
262,589 |
|
|
233,121 |
Other current assets (1) |
|
|
52,405 |
|
|
43,574 |
Total current assets |
|
|
509,057 |
|
|
409,834 |
Property and equipment, net |
|
|
57,676 |
|
|
53,549 |
Goodwill and intangible assets, net |
|
|
1,395,511 |
|
|
1,415,000 |
Equity investment |
|
|
83,333 |
|
|
83,069 |
Operating lease right-of-use assets |
|
|
42,181 |
|
|
43,750 |
Other long-term assets |
|
|
25,226 |
|
|
22,223 |
Total assets |
|
$ |
2,112,984 |
|
$ |
2,027,425 |
|
|
|
|
|
||
Liabilities and stockholders' equity |
||||||
Current liabilities: |
|
|
|
|
||
Accounts payable |
|
$ |
38,050 |
|
$ |
8,690 |
Accrued contract payables |
|
|
314,126 |
|
|
281,586 |
Accrued expenses and other current liabilities |
|
|
138,071 |
|
|
119,563 |
Accrued transportation costs |
|
|
107,190 |
|
|
103,294 |
Current portion of operating lease liabilities |
|
|
9,858 |
|
|
9,873 |
Deferred revenue |
|
|
5,648 |
|
|
4,228 |
Total current liabilities |
|
|
612,943 |
|
|
527,234 |
Long-term debt, net of deferred financing costs |
|
|
976,233 |
|
|
975,225 |
Operating lease liabilities, less current portion |
|
|
34,092 |
|
|
34,524 |
Long-term contracts payables |
|
|
1,893 |
|
|
— |
Other long-term liabilities (2) |
|
|
111,623 |
|
|
117,175 |
Total liabilities |
|
|
1,736,784 |
|
|
1,654,158 |
|
|
|
|
|
||
Stockholders' equity |
|
|
|
|
||
Stockholders' equity |
|
|
376,200 |
|
|
373,267 |
Total liabilities and stockholders' equity |
|
$ |
2,112,984 |
|
$ |
2,027,425 |
(1) |
Includes other receivables, prepaid expenses and other current assets and short-term restricted cash. |
|
(2) |
Includes other long-term liabilities and deferred tax liabilities. |
Modivcare Inc. |
||||||||
Unaudited Condensed Consolidated Statements of Cash Flows |
||||||||
(in thousands) |
||||||||
|
|
|
|
|
||||
|
|
Three months ended March 31, |
||||||
|
|
|
2022 |
|
|
|
2021 |
|
Operating activities |
|
|
|
|
||||
Net income |
|
$ |
318 |
|
|
$ |
18,840 |
|
Depreciation and amortization |
|
|
23,946 |
|
|
|
12,239 |
|
Stock-based compensation |
|
|
2,049 |
|
|
|
1,187 |
|
Equity in net income of investee |
|
|
(483 |
) |
|
|
(4,503 |
) |
Deferred income taxes |
|
|
(6,587 |
) |
|
|
(616 |
) |
Reduction of right-of-use asset |
|
|
2,884 |
|
|
|
2,745 |
|
Other non-cash items (1) |
|
|
(777 |
) |
|
|
608 |
|
Changes in working capital (2) |
|
|
47,720 |
|
|
|
104,064 |
|
Net cash provided by operating activities |
|
|
69,070 |
|
|
|
134,564 |
|
|
|
|
|
|
||||
Investing activities |
|
|
|
|
||||
Purchase of property and equipment |
|
|
(8,584 |
) |
|
|
(5,388 |
) |
Net cash used in investing activities |
|
|
(8,584 |
) |
|
|
(5,388 |
) |
|
|
|
|
|
||||
Financing activities |
|
|
|
|
||||
Repurchase of common stock, for treasury |
|
|
— |
|
|
|
(14,450 |
) |
Proceeds from common stock issued pursuant to stock option exercise |
|
|
1,138 |
|
|
|
2,286 |
|
Restricted stock surrendered for employee tax payment |
|
|
(572 |
) |
|
|
(721 |
) |
Other financing activities |
|
|
— |
|
|
|
(40 |
) |
Net cash provided by (used in) financing activities |
|
|
566 |
|
|
|
(12,925 |
) |
|
|
|
|
|
||||
Net change in cash, cash equivalents and restricted cash |
|
|
61,052 |
|
|
|
116,251 |
|
Cash, cash equivalents and restricted cash at beginning of period |
|
|
133,422 |
|
|
|
183,356 |
|
Cash, cash equivalents and restricted cash at end of period |
|
$ |
194,474 |
|
|
$ |
299,607 |
|
(1) |
Includes provision for doubtful accounts and amortization of deferred financing costs and debt discount. |
|
(2)
|
Includes accounts receivable and other receivables, prepaid expenses and other current assets, self-funded insurance programs, accrued contract payables, accounts payable and accrued expenses, accrued transportation costs, deferred revenue and other long-term liabilities. |
|
Modivcare Inc.
|
|||||||||||||||||
|
Three months ended March 31, 2022 |
||||||||||||||||
|
NEMT |
|
Personal Care |
|
RPM |
|
Corporate (3) |
|
Total |
||||||||
|
|
|
|
|
|
|
|
|
|
||||||||
Service revenue, net |
$ |
400,920 |
|
$ |
159,698 |
|
$ |
13,857 |
|
|
$ |
— |
|
|
$ |
574,475 |
|
Grant income |
|
— |
|
|
468 |
|
|
— |
|
|
|
— |
|
|
|
468 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
||||||||
Service expense |
|
332,096 |
|
|
122,232 |
|
|
4,987 |
|
|
|
— |
|
|
|
459,315 |
|
General and administrative expense |
|
37,333 |
|
|
23,133 |
|
|
4,962 |
|
|
|
11,380 |
|
|
|
76,808 |
|
Depreciation and amortization |
|
7,105 |
|
|
12,505 |
|
|
4,128 |
|
|
|
208 |
|
|
|
23,946 |
|
Total operating expenses |
|
376,534 |
|
|
157,870 |
|
|
14,077 |
|
|
|
11,588 |
|
|
|
560,069 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Operating income (loss) |
|
24,386 |
|
|
2,296 |
|
|
(220 |
) |
|
|
(11,588 |
) |
|
|
14,874 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Interest expense, net |
|
— |
|
|
— |
|
|
— |
|
|
|
15,400 |
|
|
|
15,400 |
|
Income (loss) before income taxes and equity method investment |
|
24,386 |
|
|
2,296 |
|
|
(220 |
) |
|
|
(26,988 |
) |
|
|
(526 |
) |
Provision (benefit) for income taxes |
|
6,575 |
|
|
640 |
|
|
(58 |
) |
|
|
(7,518 |
) |
|
|
(361 |
) |
Equity in net loss (income) of investee, net of tax |
|
65 |
|
|
— |
|
|
— |
|
|
|
(548 |
) |
|
|
(483 |
) |
Net Income (loss) |
|
17,746 |
|
|
1,656 |
|
|
(162 |
) |
|
|
(18,922 |
) |
|
|
318 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Interest expense, net |
|
— |
|
|
— |
|
|
— |
|
|
|
15,400 |
|
|
|
15,400 |
|
Provision (benefit) for income taxes |
|
6,575 |
|
|
640 |
|
|
(58 |
) |
|
|
(7,518 |
) |
|
|
(361 |
) |
Depreciation and amortization |
|
7,105 |
|
|
12,505 |
|
|
4,128 |
|
|
|
208 |
|
|
|
23,946 |
|
EBITDA |
|
31,426 |
|
|
14,801 |
|
|
3,908 |
|
|
|
(10,832 |
) |
|
|
39,303 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Restructuring and related charges (1) |
|
5,604 |
|
|
181 |
|
|
24 |
|
|
|
31 |
|
|
|
5,840 |
|
Transaction costs (2) |
|
— |
|
|
1,273 |
|
|
647 |
|
|
|
1,791 |
|
|
|
3,711 |
|
Cash settled equity |
|
— |
|
|
— |
|
|
— |
|
|
|
(13 |
) |
|
|
(13 |
) |
Stock-based compensation |
|
— |
|
|
17 |
|
|
29 |
|
|
|
1,420 |
|
|
|
1,466 |
|
COVID-19 related costs, net of grant income |
|
122 |
|
|
349 |
|
|
— |
|
|
|
— |
|
|
|
471 |
|
Equity in net loss (income) of investee, net of tax |
|
65 |
|
|
— |
|
|
— |
|
|
|
(548 |
) |
|
|
(483 |
) |
|
|
|
|
|
|
|
|
|
|
||||||||
Adjusted EBITDA |
$ |
37,217 |
|
$ |
16,621 |
|
$ |
4,608 |
|
|
$ |
(8,151 |
) |
|
$ |
50,295 |
|
| (1) | Restructuring and related charges include professional services costs and severance and recruiting costs. |
|
| (2) | Transaction costs include SOX integration efforts at recently acquired subsidiaries and acquisition costs. |
|
| (3) | Effective January 1, 2022, the Company completed its segment reorganization which resulted in the addition of a Corporate segment that includes the costs associated with the Company's corporate operations. Through this reorganization, it was also determined that the Matrix Investment is no longer a reportable segment, and is now reported within the Corporate segment. Prior period segment amounts have been reclassified to conform to the current presentation. |
|
Modivcare Inc.
|
|||||||||||||||
|
Three months ended March 31, 2021 |
||||||||||||||
|
NEMT |
|
Personal Care |
|
Corporate (4) |
|
Total |
||||||||
|
|
|
|
|
|
|
|
||||||||
Service revenue, net |
$ |
343,416 |
|
|
$ |
110,194 |
|
|
$ |
— |
|
|
$ |
453,610 |
|
Grant income |
|
— |
|
|
|
2,648 |
|
|
|
— |
|
|
|
2,648 |
|
|
|
|
|
|
|
|
|
||||||||
Operating expenses: |
|
|
|
|
|
|
|
||||||||
Service expense |
|
272,416 |
|
|
|
87,917 |
|
|
|
— |
|
|
|
360,333 |
|
General and administrative expense |
|
27,987 |
|
|
|
15,029 |
|
|
|
11,909 |
|
|
|
54,925 |
|
Depreciation and amortization |
|
7,312 |
|
|
|
4,927 |
|
|
|
— |
|
|
|
12,239 |
|
Total operating expenses |
|
307,715 |
|
|
|
107,873 |
|
|
|
11,909 |
|
|
|
427,497 |
|
|
|
|
|
|
|
|
|
||||||||
Operating income (loss) |
|
35,701 |
|
|
|
4,969 |
|
|
|
(11,909 |
) |
|
|
28,761 |
|
|
|
|
|
|
|
|
|
||||||||
Interest expense, net |
|
— |
|
|
|
— |
|
|
|
8,423 |
|
|
|
8,423 |
|
Income (loss) before income taxes and equity method investment |
|
35,701 |
|
|
|
4,969 |
|
|
|
(20,332 |
) |
|
|
20,338 |
|
Provision (benefit) for income taxes |
|
9,404 |
|
|
|
1,438 |
|
|
|
(6,103 |
) |
|
|
4,739 |
|
Equity in net income of investee, net of tax |
|
— |
|
|
|
— |
|
|
|
(3,241 |
) |
|
|
(3,241 |
) |
Net Income (loss) |
|
26,297 |
|
|
|
3,531 |
|
|
|
(10,988 |
) |
|
|
18,840 |
|
|
|
|
|
|
|
|
|
||||||||
Interest expense, net |
|
— |
|
|
|
— |
|
|
|
8,423 |
|
|
|
8,423 |
|
Provision (benefit) for income taxes |
|
9,404 |
|
|
|
1,438 |
|
|
|
(6,103 |
) |
|
|
4,739 |
|
Depreciation and amortization |
|
7,312 |
|
|
|
4,927 |
|
|
|
— |
|
|
|
12,239 |
|
EBITDA |
|
43,013 |
|
|
|
9,896 |
|
|
|
(8,668 |
) |
|
|
44,241 |
|
|
|
|
|
|
|
|
|
||||||||
Restructuring and related charges (1) |
|
3,494 |
|
|
|
— |
|
|
|
151 |
|
|
|
3,645 |
|
Transaction costs (2) |
|
(37 |
) |
|
|
1,045 |
|
|
|
2,670 |
|
|
|
3,678 |
|
Cash settled equity (3) |
|
— |
|
|
|
— |
|
|
|
2,093 |
|
|
|
2,093 |
|
Stock-based compensation |
|
— |
|
|
|
— |
|
|
|
1,131 |
|
|
|
1,131 |
|
COVID-19 related costs, net of grant income |
|
339 |
|
|
|
(1,852 |
) |
|
|
— |
|
|
|
(1,513 |
) |
Equity in net income of investee, net of tax |
|
— |
|
|
|
— |
|
|
|
(3,241 |
) |
|
|
(3,241 |
) |
|
|
|
|
|
|
|
|
||||||||
Adjusted EBITDA |
$ |
46,809 |
|
|
$ |
9,089 |
|
|
$ |
(5,864 |
) |
|
$ |
50,034 |
|
| (1) | Restructuring and related charges include professional services costs of $3.2 million and severance and office closure costs of $0.4 million. |
|
| (2) | Transaction costs include Circulation management incentive plan costs and acquisition costs related to Simplura Health Group and National MedTrans. |
|
| (3) | Adjusted EBITDA for Q1 2021 was recast to show the impact of cash settled equity, which the Company is now including for the purpose of this calculation. |
|
| (4) | Effective January 1, 2022, the Company completed its segment reorganization which resulted in the addition of a Corporate segment that includes the costs associated with the Company's corporate operations. Through this reorganization, it was also determined that the Matrix Investment is no longer a reportable segment, and is now reported within the Corporate segment. Prior period segment amounts have been reclassified to conform to the current presentation, with the exception of the RPM segment, which is not included in Q1 of 2021 as it was purchased in Q3 of 2021. |
|
Modivcare Inc.
|
|||||||
|
Three months ended March 31, |
||||||
|
|
2022 |
|
|
|
2021 |
|
|
|
|
|
||||
Net income |
$ |
318 |
|
|
$ |
18,840 |
|
|
|
|
|
||||
Restructuring and related charges(1) |
|
5,840 |
|
|
|
3,645 |
|
Transaction costs(2) |
|
3,711 |
|
|
|
3,678 |
|
Cash settled equity(3) |
|
(13 |
) |
|
|
2,093 |
|
Stock-based compensation |
|
1,466 |
|
|
|
1,131 |
|
Equity in net income of investee, net of tax |
|
(483 |
) |
|
|
(3,241 |
) |
Intangible amortization expense |
|
19,490 |
|
|
|
9,502 |
|
COVID-19 related costs, net of grant income |
|
471 |
|
|
|
(1,513 |
) |
Tax effected impact of adjustments |
|
(8,629 |
) |
|
|
(4,536 |
) |
|
|
|
|
||||
Adjusted Net Income |
$ |
22,171 |
|
|
$ |
29,599 |
|
|
|
|
|
||||
Adjusted EPS |
$ |
1.57 |
|
|
$ |
2.06 |
|
|
|
|
|
||||
Diluted weighted-average number of common shares outstanding |
|
14,143,548 |
|
|
|
14,362,226 |
|
| (1) | Restructuring and related charges include severance, organizational consolidation costs and professional fees. |
|
| (2) | Transaction costs include certain transaction-related expenses and SOX integration efforts. |
|
| (3) | Adjusted net income for Q1 2021 was recast to show the impact of cash-settled equity, which the Company is now including for the purpose of this calculation. |
|
Modivcare Inc.
|
||||||||||
|
Three months ended |
|
|
|||||||
|
March 31, 2022 |
|
March 31, 2021 |
|
% Change |
|||||
|
|
|
|
|
|
|||||
NEMT Segment |
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
Service revenue, net |
$ |
400,920 |
|
|
$ |
343,416 |
|
|
16.7 |
% |
Service expense; purchased services |
|
277,947 |
|
|
|
223,294 |
|
|
24.5 |
% |
Service expense; payroll, and other |
|
54,149 |
|
|
|
49,122 |
|
|
10.2 |
% |
Gross profit |
$ |
68,824 |
|
|
$ |
71,000 |
|
|
(3.1 |
) % |
Gross margin |
|
17.2 |
% |
|
|
20.7 |
% |
|
|
|
|
|
|
|
|
|
|||||
G&A expense |
$ |
37,333 |
|
|
$ |
27,987 |
|
|
33.4 |
% |
G&A expense adjustments |
|
|
|
|
|
|||||
Restructuring and related charges |
|
5,604 |
|
|
|
3,494 |
|
|
60.4 |
% |
Transaction costs |
|
— |
|
|
|
(37 |
) |
|
(100.0 |
) % |
Adjusted G&A expense |
$ |
31,729 |
|
|
$ |
24,530 |
|
|
29.3 |
% |
Adjusted G&A expense % of revenue |
|
7.9 |
% |
|
|
7.1 |
% |
|
|
|
|
|
|
|
|
|
|||||
Net income |
$ |
17,746 |
|
|
$ |
26,297 |
|
|
(32.5 |
) % |
Net income margin |
|
4.4 |
% |
|
|
7.7 |
% |
|
|
|
|
|
|
|
|
|
|||||
Adjusted EBITDA |
$ |
37,217 |
|
|
$ |
46,809 |
|
|
(20.5 |
) % |
Adjusted EBITDA margin |
|
9.3 |
% |
|
|
13.6 |
% |
|
|
|
Modivcare Inc.
|
||||||||||
|
Three months ended |
|
|
|||||||
|
March 31, 2022 |
|
March 31, 2021 |
|
% Change |
|||||
|
|
|
|
|
|
|||||
Personal Care Segment |
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
Service revenue, net |
$ |
159,698 |
|
|
$ |
110,194 |
|
|
44.9 |
% |
Service expense |
|
122,232 |
|
|
|
87,917 |
|
|
39.0 |
% |
Gross profit |
$ |
37,466 |
|
|
$ |
22,277 |
|
|
68.2 |
% |
Gross Margin |
|
23.5 |
% |
|
|
20.2 |
% |
|
|
|
|
|
|
|
|
|
|||||
G&A expense |
$ |
23,133 |
|
|
$ |
15,029 |
|
|
53.9 |
% |
G&A expense adjustments |
|
|
|
|
|
|||||
Restructuring and related charges |
|
181 |
|
|
|
— |
|
|
NA |
|
Transaction costs |
|
1,273 |
|
|
|
1,045 |
|
|
21.8 |
% |
Stock-based compensation |
|
17 |
|
|
|
— |
|
|
NA |
|
Adjusted G&A expense |
$ |
21,662 |
|
|
$ |
13,984 |
|
|
54.9 |
% |
Adjusted G&A expense % of revenue |
|
13.6 |
% |
|
|
12.7 |
% |
|
|
|
|
|
|
|
|
|
|||||
Net income |
$ |
1,656 |
|
|
$ |
3,531 |
|
|
(53.1 |
) % |
Net income margin |
|
1.0 |
% |
|
|
3.2 |
% |
|
|
|
|
|
|
|
|
|
|||||
Adjusted EBITDA |
$ |
16,621 |
|
|
$ |
9,089 |
|
|
82.9 |
% |
Adjusted EBITDA margin |
|
10.4 |
% |
|
|
8.2 |
% |
|
|
|
|
|
|
|
|
|
|||||
RPM Segment |
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
Service revenue, net |
$ |
13,857 |
|
|
|
|
|
|||
Service expense |
|
4,987 |
|
|
|
|
|
|||
Gross profit |
$ |
8,870 |
|
|
|
|
|
|||
Gross Margin |
|
64.0 |
% |
|
|
|
|
|||
|
|
|
|
|
|
|||||
G&A expense |
$ |
4,962 |
|
|
|
|
|
|||
G&A expense adjustments |
|
|
|
|
|
|||||
Restructuring and related charges |
|
24 |
|
|
|
|
|
|||
Transaction costs |
|
647 |
|
|
|
|
|
|||
Stock-based compensation |
|
29 |
|
|
|
|
|
|||
Adjusted G&A expense |
$ |
4,262 |
|
|
|
|
|
|||
Adjusted G&A expense % of revenue |
|
30.8 |
% |
|
|
|
|
|||
|
|
|
|
|
|
|||||
Net loss |
$ |
(162 |
) |
|
|
|
|
|||
Net loss margin |
|
(1.2 |
) % |
|
|
|
|
|||
|
|
|
|
|
|
|||||
Adjusted EBITDA |
$ |
4,608 |
|
|
|
|
|
|||
Adjusted EBITDA margin |
|
33.3 |
% |
|
|
|
|
|||
Modivcare Inc.
|
||||||||||
|
Three months ended |
|
|
|||||||
|
March 31, 2022 |
|
March 31, 2021 |
|
% Change |
|||||
|
|
|
|
|
|
|||||
Corporate Segment |
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
G&A expense |
$ |
11,380 |
|
|
$ |
11,909 |
|
|
(4.4 |
) % |
G&A expense adjustments |
|
|
|
|
|
|||||
Restructuring and related charges |
|
31 |
|
|
|
151 |
|
|
(79.5 |
) % |
Transaction costs |
|
1,791 |
|
|
|
2,670 |
|
|
(32.9 |
) % |
Cash settled equity |
|
(13 |
) |
|
|
2,093 |
|
|
(100.6 |
) % |
Stock-based compensation |
|
1,420 |
|
|
|
1,131 |
|
|
25.6 |
% |
Adjusted G&A expense |
$ |
8,151 |
|
|
$ |
5,864 |
|
|
39.0 |
% |
Adjusted G&A expense % of consolidated revenue |
|
1.4 |
% |
|
|
1.3 |
% |
|
|
|
ДЕНВЕР -- (BUSINESS WIRE)-- ModivCare Inc. (“Компания” или “ModivCare”) (Nasdaq: MODV), технологичная компания в области здравоохранения, предоставляющая платформу комплексных решений для поддерживающей терапии, ориентированных на улучшение результатов лечения пациентов, сегодня сообщила о финансовых результатах за три месяца, закончившихся 31 марта, 2022 год.
Основные моменты первого квартала 2022 года:
“В этом квартале мы продвинули нашу стратегию по улучшению результатов и лучшему удовлетворению медицинских потребностей пациентов с помощью нашей платформы поддерживающей терапии”, - сказал Дэниел Э. Гринлиф, президент и главный исполнительный директор ModivCare. “Я очень доволен недавними назначениями руководства в ModivCare, которые помогут нам достичь ключевых операционных целей и целей роста. Благодаря дисциплинированному исполнению со стороны нашей команды и увеличению темпов работы в этом квартале, ModivCare стремится решать социальные детерминанты здоровья и устранять препятствия для доступа к медицинской помощи для 32 миллионов членов, которых мы обслуживаем. Я чрезвычайно горжусь невероятной работой и самоотверженностью всей нашей организации, направленной на ускорение реализации нашего видения расширения возможностей пациентов получать доступ к медицинской помощи через нашу интегрированную платформу более легко, эффективно и эффективно ”.
Результаты первого квартала 2022 года
За первый квартал 2022 года Компания сообщила о выручке в размере 574,5 млн долларов, увеличившись на 26,6% по сравнению с 453,6 млн долларов в первом квартале 2021 года.
Операционная прибыль в первом квартале 2022 года составила 14,9 млн долларов, или 2,6% от выручки, по сравнению с операционной прибылью в размере 28,8 млн долларов, или 6,3% от выручки, в первом квартале 2021 года. Чистая прибыль в первом квартале 2022 года составила $0,3 млн, или $0,02 на разводненную обыкновенную акцию, по сравнению с чистой прибылью в размере $18,8 млн, или $1,31 на разводненную обыкновенную акцию, в первом квартале 2021 года.
Скорректированная EBITDA составила $50,3 млн, или 8,8% от выручки, в первом квартале 2022 года по сравнению с $50,0 млн, или 11,0% от выручки, в первом квартале 2021 года.
Скорректированная чистая прибыль в первом квартале 2022 года составила 22,2 млн долларов, или 1,57 доллара на разводненную обыкновенную акцию, по сравнению с 29,6 млн долларов, или 2,06 доллара на разводненную обыкновенную акцию, в первом квартале 2021 года.
Сопоставимая скорректированная EBITDA и Скорректированная Чистая прибыль за 1 квартал 2021 года были пересчитаны, чтобы показать влияние собственного капитала, рассчитанного денежными средствами, который Компания в настоящее время исключает для целей этих расчетов.
Увеличение выручки по сравнению с предыдущим годом произошло в основном за счет увеличения выручки в размере 44,4 млн долларов США и 13,9 млн долларов США, связанных с приобретением Care Finders и VRI, соответственно. Выручка NEMT также увеличилась в годовом исчислении из-за увеличения объема поездок, что привело к увеличению дохода на одного участника в 1 квартале 2022 года.
Скорректированная EBITDA увеличилась в первом квартале 2022 года благодаря дополнительному вкладу со стороны Care Finders и VRI. Это было частично компенсировано более высокими корпоративными общими и административными расходами, поскольку Компания продолжала инвестировать в своих сотрудников и технологии.
ModivCare зафиксировала доход за вычетом налогов в размере 0,5 миллиона долларов, связанный с инвестициями в акции Matrix в 1 квартале 2022 года, по сравнению с 3,2 миллионами долларов за первый квартал 2021 года.
Организационная консолидация и изменения в сегментах
С 1 января 2022 года Компания завершила реорганизацию своего сегмента, в результате которой был добавлен Корпоративный сегмент, включающий расходы, связанные с корпоративными операциями Компании. Операционные результаты нашего Корпоративного сегмента включают нашу деятельность, связанную с руководством, бухгалтерией, финансами, внутренним аудитом, налогами, юридическими и определенными стратегическими функциями и функциями корпоративного развития для каждого сегмента, а также программу кэптивного страхования Компании и результаты наших матричных инвестиций. Компания реклассифицировала определенные расходы, связанные с этой реорганизацией, за три месяца, закончившихся 31 марта 2021 года, в соответствии с настоящей презентацией.
Презентация инвестора и Телефонная конференция
ModivCare проведет телефонную конференцию для обсуждения своих финансовых результатов в четверг, 5 мая 2022 года, в 8:00 утра по восточному времени. Чтобы получить доступ к вызову, пожалуйста, наберите:
Бесплатный звонок в США: 1 (877) 423 9820 Международный: 1 (201) 493 6749
Вы также можете получить доступ к телефонной конференции через веб-трансляцию на сайте investors.ModivCare.com , где вызов также будет заархивирован.
Об ModivCare
ModivCare Inc. (“ModivCare”) (Nasdaq: MODV) - технологичная компания в области здравоохранения, предоставляющая платформу комплексных решений для оказания поддерживающей помощи государственным и частным плательщикам и их пациентам. Наши решения, основанные на ценности, учитывают социальные детерминанты здоровья (SDoH), обеспечивают более широкий доступ к медицинской помощи, снижают затраты и улучшают результаты. Мы являемся ведущим поставщиком услуг неаварийной медицинской транспортировки (NEMT), личной гигиены и дистанционного наблюдения за пациентами. Чтобы узнать больше об ModivCare, пожалуйста, посетите www.ModivCare.com .
Финансовые показатели и корректировки, не относящиеся к ОПБУ
В дополнение к финансовым показателям, подготовленным в соответствии с общепринятыми принципами бухгалтерского учета в Соединенных Штатах ("GAAP"), настоящий пресс-релиз включает показатель EBITDA, Скорректированный показатель EBITDA и Скорректированную рентабельность по EBITDA для Компании и ее сегментов, Скорректированную чистую прибыль и Скорректированную прибыль на акцию для Компании, а также Скорректированные расходы на сегменты Компании, которые являются показателями эффективности, которые не признаются в соответствии с GAAP. Показатель EBITDA определяется как доход (убыток) от продолжающейся деятельности, за вычетом налогов, до: (1) процентных расходов, нетто, (2) резерва (льготы) по налогу на прибыль и (3) износа и амортизации. Скорректированный показатель EBITDA рассчитывается как показатель EBITDA до (в зависимости от обстоятельств): (1) реструктуризация и связанные с ней расходы, включая выходное пособие, закрытие офиса и расходы на профессиональные услуги, (2) определенные операционные и связанные с ними расходы, (3) собственный капитал, рассчитанный наличными, (4) компенсация на основе акций, (5) COVID-19 соответствующие расходы, за вычетом дохода от гранта, и (6) доля в чистых убытках (доходах) объекта инвестиций. Скорректированная рентабельность по EBITDA рассчитывается как Скорректированная EBITDA, деленная на выручку от услуг, нетто. Скорректированный чистый доход рассчитывается как доход от продолжающейся деятельности, за вычетом налогов, до: (1) реструктуризации и связанных с ней расходов, включая выходное пособие и закрытие офиса, а также расходы на профессиональные услуги, (2) определенные операционные и связанные с ними расходы, (3) собственный капитал, рассчитанный наличными, (4) компенсация на основе акций, (5) собственный капитал в чистых убытках (доходах) объекта инвестиций, (6) расходы на нематериальную амортизацию, (7) расходы, связанные с COVID-19, за вычетом доходов от грантов, (8) налоговые последствия Закона о помощи, помощи и экономической безопасности в связи с коронавирусом ("Закон о заботах") и (9) влияние таких корректировок на подоходный налог. Скорректированная прибыль на акцию рассчитывается как Скорректированная Чистая прибыль за вычетом (если применимо): суммы (1) дивидендов по конвертируемым привилегированным акциям плюс (2) дохода, распределенного по участвующим ценным бумагам, деленной на разводненное средневзвешенное количество обыкновенных акций в обращении, рассчитанное для Скорректированной чистой прибыли. Скорректированные расходы на G&A рассчитываются как расходы на G& A до (в зависимости от обстоятельств): (1) реструктуризации и связанных с ней расходов, (2) затрат по сделке, (3) собственного капитала, рассчитанного наличными, и (4) компенсации на основе акций. Наши показатели эффективности, не относящиеся к GAAP, исключают расходы и суммы, которые не зависят от наших основных операционных результатов и могут носить одноразовый характер. Исключение этих расходов делает сравнение с предыдущими периодами, а также с другими компаниями в нашей отрасли более значимым. Мы считаем, что такие меры позволяют инвесторам лучше понять факторы и тенденции, влияющие на текущую деятельность нашего бизнеса. Мы считаем, что наша основная деятельность - это текущая деятельность по предоставлению услуг, от которой мы получаем доход, включая прямые операционные расходы и косвенные расходы на поддержку этой деятельности. Кроме того, наша чистая прибыль или убыток по объекту долевых инвестиций исключаются из этих показателей, поскольку у нас нет возможности управлять предприятием, распределять ресурсы внутри предприятия или напрямую контролировать его деятельность или результаты.
Наши финансовые показатели, не относящиеся к GAAP, могут не предоставлять информацию, непосредственно сопоставимую с информацией, предоставляемой другими компаниями в нашей отрасли, поскольку другие компании в нашей отрасли могут рассчитывать финансовые показатели, не относящиеся к GAAP, по-другому. Кроме того, существуют ограничения в использовании финансовых показателей, не относящихся к GAAP, поскольку они не подготовлены в соответствии с GAAP, могут отличаться от финансовых показателей, не относящихся к GAAP, используемых другими компаниями, и исключают расходы, которые могут оказать существенное влияние на наши отчетные финансовые результаты. Представление финансовых показателей, не относящихся к ОПБУ, не предназначено для рассмотрения отдельно или в качестве замены наиболее непосредственно сопоставимых финансовых показателей, подготовленных в соответствии с ОПБУ. Мы настоятельно призываем вас пересмотреть сверку наших финансовых показателей, не относящихся к GAAP, с наиболее непосредственно сопоставимыми финансовыми показателями GAAP, включенными ниже, и не полагаться на какой-либо отдельный финансовый показатель для оценки нашего бизнеса.
Прогнозные заявления
Некоторые заявления, содержащиеся в настоящем пресс-релизе, представляют собой “прогнозные заявления” по смыслу Закона о реформе судебных разбирательств по частным ценным бумагам 1995 года. Эти утверждения носят прогностический характер и часто идентифицируются с помощью таких терминов, как “может”, “будет”, “должен”, “ожидать”, “полагать”, “оценивать”, “намереваться” и подобных слов, указывающих на возможные будущие ожидания, события или действия. Такие прогнозные заявления основаны на текущих ожиданиях, предположениях, оценках и прогнозах относительно нашего бизнеса и нашей отрасли и не являются гарантией наших будущих результатов. Эти заявления подвержены ряду с известными и неизвестными рисками, неопределенностями и другими факторами, многие из которых находятся за пределами нашей возможности контролировать или предсказать, что может привести фактические события могут существенно отличаться от выраженных или подразумеваемых в настоящем документе, включая, но не ограничиваясь: государственные или частные страховые программы финансирования сокращений и ограничений; альтернативные платежные моделей или переход Медикейд и Медикер для управляемой медицинской помощи, организации или МКО; в нашей неспособности контролировать ставки возмещения, полученные за наши услуги; стоимость сдерживание инициативы частная сторонних плательщиков; последствия для здоровья населения чрезвычайной ситуации; недостатки или нарушения безопасности наших информационно-технических систем, включая системы, предназначенные для защиты наших клиентов конфиденциальности и конфиденциальную информацию; какие-либо изменения в финансировании, финансовой устойчивости и наши взаимоотношения с финансовыми организациями; пандемия инфекционных заболеваний, включая COVID-19 пандемией; перебои в наш контакт-центр Операции причиненного здоровью эпидемий или пандемий COVID-19; из-за задержек в коллекции или коллекции наши дебиторской задолженности, особенно во время любой бизнес-интеграции; нарушения наших долгосрочных активов; невозможность поддержания или дальнейшего развития надежной, эффективной и безопасной информационно-технологических систем; невозможность привлечения и удержания квалифицированных работников; приобретение или приобретение интеграции усилий; в наших договорах выжившие до конца своих заявленных сроков, или не быть возобновлен или продлен; наша неспособность эффективно конкурировать на рынке; наши не заключить контракты через государственную запроса предложений процесса, или наши контракты не выгодно; любое невыполнение договорных обязательств или для поддержания существующих залоге производительности и оплаты облигаций; неспособность точно оценить стоимость выполнения наших контрактов; любой классификации водители, которых мы привлекаем в качестве независимых подрядчиков, а не сотрудников; значительные перерывы в нашем общении и передачи данных; не успешного выполнения нашей стратегии в условиях нашей конкуренции; невозможность поддерживать отношения с существующими пациента источники; невозможность получить согласие от Нью-Йоркского департамента здравоохранения, чтобы управлять ежедневными операциями наших лицензию на дому личной гигиены услуги агентства бизнес, который мы приобрели с нашим личной гигиены сегменте; приобрели неизвестных обязательства в связи с приобретением наш личной гигиены сегменте; изменения в деле-микс из нашей личной гигиены больных, или изменение плательщика смеси или оплаты методикам; наши потери существующих благоприятных управляемой медицинской помощи контрактов; наш испытывают дефицит в квалифицированных сотрудников и управления; трудовых споров или нарушений, в частности, в Нью-Йорке, становятся предметом злоупотребления служебным положением или других подобных претензий; и наша зависимость от других финансовое состояние инвестиции в Матрице.
Компания предоставила дополнительную информацию о рисках, с которыми сталкивается наш бизнес, в нашем годовом отчете по форме 10-K и последующих документах, которые были недавно поданы в Комиссию по ценным бумагам и биржам. Мы предостерегаем вас от чрезмерного доверия к этим прогнозным заявлениям, которые относятся только к дате, на которую было сделано заявление, и полностью квалифицируются предостерегающими заявлениями, изложенными в настоящем документе и в наших заявках в Комиссию по ценным бумагам и биржам, которые вы должны прочитать полностью, прежде чем делать инвестиционное решение в отношении наших ценных бумаг. Мы не берем на себя никаких обязательств по обновлению или пересмотру любых прогнозных заявлений, содержащихся в этом релизе, будь то в результате новой информации, будущих событий или иным образом, за исключением случаев, предусмотренных применимым законодательством.
--финансовые таблицы, за которыми нужно следить--
ModivCare Inc. |
||||||||
Unaudited Condensed Consolidated Statements of Operations |
||||||||
(in thousands, except share and per share data) |
||||||||
|
|
|
|
|
||||
|
|
Three months ended March 31, |
||||||
|
|
|
2022 |
|
|
|
2021 |
|
|
|
|
|
|
||||
Service revenue, net |
|
$ |
574,475 |
|
|
$ |
453,610 |
|
Grant income |
|
|
468 |
|
|
|
2,648 |
|
|
|
|
|
|
||||
Operating expenses: |
|
|
|
|
||||
Service expense |
|
|
459,315 |
|
|
|
360,333 |
|
General and administrative expense |
|
|
76,808 |
|
|
|
54,925 |
|
Depreciation and amortization |
|
|
23,946 |
|
|
|
12,239 |
|
Total operating expenses |
|
|
560,069 |
|
|
|
427,497 |
|
|
|
|
|
|
||||
Operating income |
|
|
14,874 |
|
|
|
28,761 |
|
|
|
|
|
|
||||
Other expenses: |
|
|
|
|
||||
Interest expense, net |
|
|
15,400 |
|
|
|
8,423 |
|
Income (loss) before income taxes and equity method investment |
|
|
(526 |
) |
|
|
20,338 |
|
Provision (benefit) for income taxes |
|
|
(361 |
) |
|
|
4,739 |
|
Equity in net income of investee, net of tax |
|
|
(483 |
) |
|
|
(3,241 |
) |
Net income |
|
$ |
318 |
|
|
$ |
18,840 |
|
|
|
|
|
|
||||
Earnings per common share: |
|
|
|
|
||||
Basic |
|
$ |
0.02 |
|
|
$ |
1.33 |
|
Diluted |
|
$ |
0.02 |
|
|
$ |
1.31 |
|
|
|
|
|
|
||||
Weighted-average number of common shares outstanding: |
|
|
|
|
||||
Basic |
|
|
14,023,585 |
|
|
|
14,158,666 |
|
Diluted |
|
|
14,143,548 |
|
|
|
14,362,226 |
|
ModivCare Inc. |
||||||
Unaudited Condensed Consolidated Balance Sheets |
||||||
(in thousands) |
||||||
|
|
|
|
|
||
|
|
March 31, 2022 |
|
December 31, 2021 |
||
Assets |
|
|
|
|
||
Current assets: |
|
|
|
|
||
Cash and cash equivalents |
|
$ |
194,063 |
|
$ |
133,139 |
Accounts receivable, net |
|
|
262,589 |
|
|
233,121 |
Other current assets (1) |
|
|
52,405 |
|
|
43,574 |
Total current assets |
|
|
509,057 |
|
|
409,834 |
Property and equipment, net |
|
|
57,676 |
|
|
53,549 |
Goodwill and intangible assets, net |
|
|
1,395,511 |
|
|
1,415,000 |
Equity investment |
|
|
83,333 |
|
|
83,069 |
Operating lease right-of-use assets |
|
|
42,181 |
|
|
43,750 |
Other long-term assets |
|
|
25,226 |
|
|
22,223 |
Total assets |
|
$ |
2,112,984 |
|
$ |
2,027,425 |
|
|
|
|
|
||
Liabilities and stockholders' equity |
||||||
Current liabilities: |
|
|
|
|
||
Accounts payable |
|
$ |
38,050 |
|
$ |
8,690 |
Accrued contract payables |
|
|
314,126 |
|
|
281,586 |
Accrued expenses and other current liabilities |
|
|
138,071 |
|
|
119,563 |
Accrued transportation costs |
|
|
107,190 |
|
|
103,294 |
Current portion of operating lease liabilities |
|
|
9,858 |
|
|
9,873 |
Deferred revenue |
|
|
5,648 |
|
|
4,228 |
Total current liabilities |
|
|
612,943 |
|
|
527,234 |
Long-term debt, net of deferred financing costs |
|
|
976,233 |
|
|
975,225 |
Operating lease liabilities, less current portion |
|
|
34,092 |
|
|
34,524 |
Long-term contracts payables |
|
|
1,893 |
|
|
— |
Other long-term liabilities (2) |
|
|
111,623 |
|
|
117,175 |
Total liabilities |
|
|
1,736,784 |
|
|
1,654,158 |
|
|
|
|
|
||
Stockholders' equity |
|
|
|
|
||
Stockholders' equity |
|
|
376,200 |
|
|
373,267 |
Total liabilities and stockholders' equity |
|
$ |
2,112,984 |
|
$ |
2,027,425 |
(1) |
Includes other receivables, prepaid expenses and other current assets and short-term restricted cash. |
|
(2) |
Includes other long-term liabilities and deferred tax liabilities. |
ModivCare Inc. |
||||||||
Unaudited Condensed Consolidated Statements of Cash Flows |
||||||||
(in thousands) |
||||||||
|
|
|
|
|
||||
|
|
Three months ended March 31, |
||||||
|
|
|
2022 |
|
|
|
2021 |
|
Operating activities |
|
|
|
|
||||
Net income |
|
$ |
318 |
|
|
$ |
18,840 |
|
Depreciation and amortization |
|
|
23,946 |
|
|
|
12,239 |
|
Stock-based compensation |
|
|
2,049 |
|
|
|
1,187 |
|
Equity in net income of investee |
|
|
(483 |
) |
|
|
(4,503 |
) |
Deferred income taxes |
|
|
(6,587 |
) |
|
|
(616 |
) |
Reduction of right-of-use asset |
|
|
2,884 |
|
|
|
2,745 |
|
Other non-cash items (1) |
|
|
(777 |
) |
|
|
608 |
|
Changes in working capital (2) |
|
|
47,720 |
|
|
|
104,064 |
|
Net cash provided by operating activities |
|
|
69,070 |
|
|
|
134,564 |
|
|
|
|
|
|
||||
Investing activities |
|
|
|
|
||||
Purchase of property and equipment |
|
|
(8,584 |
) |
|
|
(5,388 |
) |
Net cash used in investing activities |
|
|
(8,584 |
) |
|
|
(5,388 |
) |
|
|
|
|
|
||||
Financing activities |
|
|
|
|
||||
Repurchase of common stock, for treasury |
|
|
— |
|
|
|
(14,450 |
) |
Proceeds from common stock issued pursuant to stock option exercise |
|
|
1,138 |
|
|
|
2,286 |
|
Restricted stock surrendered for employee tax payment |
|
|
(572 |
) |
|
|
(721 |
) |
Other financing activities |
|
|
— |
|
|
|
(40 |
) |
Net cash provided by (used in) financing activities |
|
|
566 |
|
|
|
(12,925 |
) |
|
|
|
|
|
||||
Net change in cash, cash equivalents and restricted cash |
|
|
61,052 |
|
|
|
116,251 |
|
Cash, cash equivalents and restricted cash at beginning of period |
|
|
133,422 |
|
|
|
183,356 |
|
Cash, cash equivalents and restricted cash at end of period |
|
$ |
194,474 |
|
|
$ |
299,607 |
|
(1) |
Includes provision for doubtful accounts and amortization of deferred financing costs and debt discount. |
|
(2)
|
Includes accounts receivable and other receivables, prepaid expenses and other current assets, self-funded insurance programs, accrued contract payables, accounts payable and accrued expenses, accrued transportation costs, deferred revenue and other long-term liabilities. |
|
ModivCare Inc.
|
|||||||||||||||||
|
Three months ended March 31, 2022 |
||||||||||||||||
|
NEMT |
|
Personal Care |
|
RPM |
|
Corporate (3) |
|
Total |
||||||||
|
|
|
|
|
|
|
|
|
|
||||||||
Service revenue, net |
$ |
400,920 |
|
$ |
159,698 |
|
$ |
13,857 |
|
|
$ |
— |
|
|
$ |
574,475 |
|
Grant income |
|
— |
|
|
468 |
|
|
— |
|
|
|
— |
|
|
|
468 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
||||||||
Service expense |
|
332,096 |
|
|
122,232 |
|
|
4,987 |
|
|
|
— |
|
|
|
459,315 |
|
General and administrative expense |
|
37,333 |
|
|
23,133 |
|
|
4,962 |
|
|
|
11,380 |
|
|
|
76,808 |
|
Depreciation and amortization |
|
7,105 |
|
|
12,505 |
|
|
4,128 |
|
|
|
208 |
|
|
|
23,946 |
|
Total operating expenses |
|
376,534 |
|
|
157,870 |
|
|
14,077 |
|
|
|
11,588 |
|
|
|
560,069 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Operating income (loss) |
|
24,386 |
|
|
2,296 |
|
|
(220 |
) |
|
|
(11,588 |
) |
|
|
14,874 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Interest expense, net |
|
— |
|
|
— |
|
|
— |
|
|
|
15,400 |
|
|
|
15,400 |
|
Income (loss) before income taxes and equity method investment |
|
24,386 |
|
|
2,296 |
|
|
(220 |
) |
|
|
(26,988 |
) |
|
|
(526 |
) |
Provision (benefit) for income taxes |
|
6,575 |
|
|
640 |
|
|
(58 |
) |
|
|
(7,518 |
) |
|
|
(361 |
) |
Equity in net loss (income) of investee, net of tax |
|
65 |
|
|
— |
|
|
— |
|
|
|
(548 |
) |
|
|
(483 |
) |
Net Income (loss) |
|
17,746 |
|
|
1,656 |
|
|
(162 |
) |
|
|
(18,922 |
) |
|
|
318 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Interest expense, net |
|
— |
|
|
— |
|
|
— |
|
|
|
15,400 |
|
|
|
15,400 |
|
Provision (benefit) for income taxes |
|
6,575 |
|
|
640 |
|
|
(58 |
) |
|
|
(7,518 |
) |
|
|
(361 |
) |
Depreciation and amortization |
|
7,105 |
|
|
12,505 |
|
|
4,128 |
|
|
|
208 |
|
|
|
23,946 |
|
EBITDA |
|
31,426 |
|
|
14,801 |
|
|
3,908 |
|
|
|
(10,832 |
) |
|
|
39,303 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Restructuring and related charges (1) |
|
5,604 |
|
|
181 |
|
|
24 |
|
|
|
31 |
|
|
|
5,840 |
|
Transaction costs (2) |
|
— |
|
|
1,273 |
|
|
647 |
|
|
|
1,791 |
|
|
|
3,711 |
|
Cash settled equity |
|
— |
|
|
— |
|
|
— |
|
|
|
(13 |
) |
|
|
(13 |
) |
Stock-based compensation |
|
— |
|
|
17 |
|
|
29 |
|
|
|
1,420 |
|
|
|
1,466 |
|
COVID-19 related costs, net of grant income |
|
122 |
|
|
349 |
|
|
— |
|
|
|
— |
|
|
|
471 |
|
Equity in net loss (income) of investee, net of tax |
|
65 |
|
|
— |
|
|
— |
|
|
|
(548 |
) |
|
|
(483 |
) |
|
|
|
|
|
|
|
|
|
|
||||||||
Adjusted EBITDA |
$ |
37,217 |
|
$ |
16,621 |
|
$ |
4,608 |
|
|
$ |
(8,151 |
) |
|
$ |
50,295 |
|
| (1) | Restructuring and related charges include professional services costs and severance and recruiting costs. |
|
| (2) | Transaction costs include SOX integration efforts at recently acquired subsidiaries and acquisition costs. |
|
| (3) | Effective January 1, 2022, the Company completed its segment reorganization which resulted in the addition of a Corporate segment that includes the costs associated with the Company's corporate operations. Through this reorganization, it was also determined that the Matrix Investment is no longer a reportable segment, and is now reported within the Corporate segment. Prior period segment amounts have been reclassified to conform to the current presentation. |
|
ModivCare Inc.
|
|||||||||||||||
|
Three months ended March 31, 2021 |
||||||||||||||
|
NEMT |
|
Personal Care |
|
Corporate (4) |
|
Total |
||||||||
|
|
|
|
|
|
|
|
||||||||
Service revenue, net |
$ |
343,416 |
|
|
$ |
110,194 |
|
|
$ |
— |
|
|
$ |
453,610 |
|
Grant income |
|
— |
|
|
|
2,648 |
|
|
|
— |
|
|
|
2,648 |
|
|
|
|
|
|
|
|
|
||||||||
Operating expenses: |
|
|
|
|
|
|
|
||||||||
Service expense |
|
272,416 |
|
|
|
87,917 |
|
|
|
— |
|
|
|
360,333 |
|
General and administrative expense |
|
27,987 |
|
|
|
15,029 |
|
|
|
11,909 |
|
|
|
54,925 |
|
Depreciation and amortization |
|
7,312 |
|
|
|
4,927 |
|
|
|
— |
|
|
|
12,239 |
|
Total operating expenses |
|
307,715 |
|
|
|
107,873 |
|
|
|
11,909 |
|
|
|
427,497 |
|
|
|
|
|
|
|
|
|
||||||||
Operating income (loss) |
|
35,701 |
|
|
|
4,969 |
|
|
|
(11,909 |
) |
|
|
28,761 |
|
|
|
|
|
|
|
|
|
||||||||
Interest expense, net |
|
— |
|
|
|
— |
|
|
|
8,423 |
|
|
|
8,423 |
|
Income (loss) before income taxes and equity method investment |
|
35,701 |
|
|
|
4,969 |
|
|
|
(20,332 |
) |
|
|
20,338 |
|
Provision (benefit) for income taxes |
|
9,404 |
|
|
|
1,438 |
|
|
|
(6,103 |
) |
|
|
4,739 |
|
Equity in net income of investee, net of tax |
|
— |
|
|
|
— |
|
|
|
(3,241 |
) |
|
|
(3,241 |
) |
Net Income (loss) |
|
26,297 |
|
|
|
3,531 |
|
|
|
(10,988 |
) |
|
|
18,840 |
|
|
|
|
|
|
|
|
|
||||||||
Interest expense, net |
|
— |
|
|
|
— |
|
|
|
8,423 |
|
|
|
8,423 |
|
Provision (benefit) for income taxes |
|
9,404 |
|
|
|
1,438 |
|
|
|
(6,103 |
) |
|
|
4,739 |
|
Depreciation and amortization |
|
7,312 |
|
|
|
4,927 |
|
|
|
— |
|
|
|
12,239 |
|
EBITDA |
|
43,013 |
|
|
|
9,896 |
|
|
|
(8,668 |
) |
|
|
44,241 |
|
|
|
|
|
|
|
|
|
||||||||
Restructuring and related charges (1) |
|
3,494 |
|
|
|
— |
|
|
|
151 |
|
|
|
3,645 |
|
Transaction costs (2) |
|
(37 |
) |
|
|
1,045 |
|
|
|
2,670 |
|
|
|
3,678 |
|
Cash settled equity (3) |
|
— |
|
|
|
— |
|
|
|
2,093 |
|
|
|
2,093 |
|
Stock-based compensation |
|
— |
|
|
|
— |
|
|
|
1,131 |
|
|
|
1,131 |
|
COVID-19 related costs, net of grant income |
|
339 |
|
|
|
(1,852 |
) |
|
|
— |
|
|
|
(1,513 |
) |
Equity in net income of investee, net of tax |
|
— |
|
|
|
— |
|
|
|
(3,241 |
) |
|
|
(3,241 |
) |
|
|
|
|
|
|
|
|
||||||||
Adjusted EBITDA |
$ |
46,809 |
|
|
$ |
9,089 |
|
|
$ |
(5,864 |
) |
|
$ |
50,034 |
|
| (1) | Restructuring and related charges include professional services costs of $3.2 million and severance and office closure costs of $0.4 million. |
|
| (2) | Transaction costs include Circulation management incentive plan costs and acquisition costs related to Simplura Health Group and National MedTrans. |
|
| (3) | Adjusted EBITDA for Q1 2021 was recast to show the impact of cash settled equity, which the Company is now including for the purpose of this calculation. |
|
| (4) | Effective January 1, 2022, the Company completed its segment reorganization which resulted in the addition of a Corporate segment that includes the costs associated with the Company's corporate operations. Through this reorganization, it was also determined that the Matrix Investment is no longer a reportable segment, and is now reported within the Corporate segment. Prior period segment amounts have been reclassified to conform to the current presentation, with the exception of the RPM segment, which is not included in Q1 of 2021 as it was purchased in Q3 of 2021. |
|
ModivCare Inc.
|
|||||||
|
Three months ended March 31, |
||||||
|
|
2022 |
|
|
|
2021 |
|
|
|
|
|
||||
Net income |
$ |
318 |
|
|
$ |
18,840 |
|
|
|
|
|
||||
Restructuring and related charges(1) |
|
5,840 |
|
|
|
3,645 |
|
Transaction costs(2) |
|
3,711 |
|
|
|
3,678 |
|
Cash settled equity(3) |
|
(13 |
) |
|
|
2,093 |
|
Stock-based compensation |
|
1,466 |
|
|
|
1,131 |
|
Equity in net income of investee, net of tax |
|
(483 |
) |
|
|
(3,241 |
) |
Intangible amortization expense |
|
19,490 |
|
|
|
9,502 |
|
COVID-19 related costs, net of grant income |
|
471 |
|
|
|
(1,513 |
) |
Tax effected impact of adjustments |
|
(8,629 |
) |
|
|
(4,536 |
) |
|
|
|
|
||||
Adjusted Net Income |
$ |
22,171 |
|
|
$ |
29,599 |
|
|
|
|
|
||||
Adjusted EPS |
$ |
1.57 |
|
|
$ |
2.06 |
|
|
|
|
|
||||
Diluted weighted-average number of common shares outstanding |
|
14,143,548 |
|
|
|
14,362,226 |
|
| (1) | Restructuring and related charges include severance, organizational consolidation costs and professional fees. |
|
| (2) | Transaction costs include certain transaction-related expenses and SOX integration efforts. |
|
| (3) | Adjusted net income for Q1 2021 was recast to show the impact of cash-settled equity, which the Company is now including for the purpose of this calculation. |
|
ModivCare Inc.
|
||||||||||
|
Three months ended |
|
|
|||||||
|
March 31, 2022 |
|
March 31, 2021 |
|
% Change |
|||||
|
|
|
|
|
|
|||||
NEMT Segment |
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
Service revenue, net |
$ |
400,920 |
|
|
$ |
343,416 |
|
|
16.7 |
% |
Service expense; purchased services |
|
277,947 |
|
|
|
223,294 |
|
|
24.5 |
% |
Service expense; payroll, and other |
|
54,149 |
|
|
|
49,122 |
|
|
10.2 |
% |
Gross profit |
$ |
68,824 |
|
|
$ |
71,000 |
|
|
(3.1 |
) % |
Gross margin |
|
17.2 |
% |
|
|
20.7 |
% |
|
|
|
|
|
|
|
|
|
|||||
G&A expense |
$ |
37,333 |
|
|
$ |
27,987 |
|
|
33.4 |
% |
G&A expense adjustments |
|
|
|
|
|
|||||
Restructuring and related charges |
|
5,604 |
|
|
|
3,494 |
|
|
60.4 |
% |
Transaction costs |
|
— |
|
|
|
(37 |
) |
|
(100.0 |
) % |
Adjusted G&A expense |
$ |
31,729 |
|
|
$ |
24,530 |
|
|
29.3 |
% |
Adjusted G&A expense % of revenue |
|
7.9 |
% |
|
|
7.1 |
% |
|
|
|
|
|
|
|
|
|
|||||
Net income |
$ |
17,746 |
|
|
$ |
26,297 |
|
|
(32.5 |
) % |
Net income margin |
|
4.4 |
% |
|
|
7.7 |
% |
|
|
|
|
|
|
|
|
|
|||||
Adjusted EBITDA |
$ |
37,217 |
|
|
$ |
46,809 |
|
|
(20.5 |
) % |
Adjusted EBITDA margin |
|
9.3 |
% |
|
|
13.6 |
% |
|
|
|
ModivCare Inc.
|
||||||||||
|
Three months ended |
|
|
|||||||
|
March 31, 2022 |
|
March 31, 2021 |
|
% Change |
|||||
|
|
|
|
|
|
|||||
Personal Care Segment |
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
Service revenue, net |
$ |
159,698 |
|
|
$ |
110,194 |
|
|
44.9 |
% |
Service expense |
|
122,232 |
|
|
|
87,917 |
|
|
39.0 |
% |
Gross profit |
$ |
37,466 |
|
|
$ |
22,277 |
|
|
68.2 |
% |
Gross Margin |
|
23.5 |
% |
|
|
20.2 |
% |
|
|
|
|
|
|
|
|
|
|||||
G&A expense |
$ |
23,133 |
|
|
$ |
15,029 |
|
|
53.9 |
% |
G&A expense adjustments |
|
|
|
|
|
|||||
Restructuring and related charges |
|
181 |
|
|
|
— |
|
|
NA |
|
Transaction costs |
|
1,273 |
|
|
|
1,045 |
|
|
21.8 |
% |
Stock-based compensation |
|
17 |
|
|
|
— |
|
|
NA |
|
Adjusted G&A expense |
$ |
21,662 |
|
|
$ |
13,984 |
|
|
54.9 |
% |
Adjusted G&A expense % of revenue |
|
13.6 |
% |
|
|
12.7 |
% |
|
|
|
|
|
|
|
|
|
|||||
Net income |
$ |
1,656 |
|
|
$ |
3,531 |
|
|
(53.1 |
) % |
Net income margin |
|
1.0 |
% |
|
|
3.2 |
% |
|
|
|
|
|
|
|
|
|
|||||
Adjusted EBITDA |
$ |
16,621 |
|
|
$ |
9,089 |
|
|
82.9 |
% |
Adjusted EBITDA margin |
|
10.4 |
% |
|
|
8.2 |
% |
|
|
|
|
|
|
|
|
|
|||||
RPM Segment |
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
Service revenue, net |
$ |
13,857 |
|
|
|
|
|
|||
Service expense |
|
4,987 |
|
|
|
|
|
|||
Gross profit |
$ |
8,870 |
|
|
|
|
|
|||
Gross Margin |
|
64.0 |
% |
|
|
|
|
|||
|
|
|
|
|
|
|||||
G&A expense |
$ |
4,962 |
|
|
|
|
|
|||
G&A expense adjustments |
|
|
|
|
|
|||||
Restructuring and related charges |
|
24 |
|
|
|
|
|
|||
Transaction costs |
|
647 |
|
|
|
|
|
|||
Stock-based compensation |
|
29 |
|
|
|
|
|
|||
Adjusted G&A expense |
$ |
4,262 |
|
|
|
|
|
|||
Adjusted G&A expense % of revenue |
|
30.8 |
% |
|
|
|
|
|||
|
|
|
|
|
|
|||||
Net loss |
$ |
(162 |
) |
|
|
|
|
|||
Net loss margin |
|
(1.2 |
) % |
|
|
|
|
|||
|
|
|
|
|
|
|||||
Adjusted EBITDA |
$ |
4,608 |
|
|
|
|
|
|||
Adjusted EBITDA margin |
|
33.3 |
% |
|
|
|
|
|||
ModivCare Inc.
|
||||||||||
|
Three months ended |
|
|
|||||||
|
March 31, 2022 |
|
March 31, 2021 |
|
% Change |
|||||
|
|
|
|
|
|
|||||
Corporate Segment |
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
G&A expense |
$ |
11,380 |
|
|
$ |
11,909 |
|
|
(4.4 |
) % |
G&A expense adjustments |
|
|
|
|
|
|||||
Restructuring and related charges |
|
31 |
|
|
|
151 |
|
|
(79.5 |
) % |
Transaction costs |
|
1,791 |
|
|
|
2,670 |
|
|
(32.9 |
) % |
Cash settled equity |
|
(13 |
) |
|
|
2,093 |
|
|
(100.6 |
) % |
Stock-based compensation |
|
1,420 |
|
|
|
1,131 |
|
|
25.6 |
% |
Adjusted G&A expense |
$ |
8,151 |
|
|
$ |
5,864 |
|
|
39.0 |
% |
Adjusted G&A expense % of consolidated revenue |
|
1.4 |
% |
|
|
1.3 |
% |
|
|
|
